Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 9Neoplasms 6Ovarian Neoplasms 3Uterine Cervical Neoplasms 1Solid Tumors 1Prostatic Neoplasms 1Peritoneal Neoplasms 1Patients With Any Advanced Solid Tumors 1Malignant Solid Tumour 1Leukemia, Myeloid, Acute 1Genital Neoplasms, Female 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

Vorinostat 2nintedanib 1dactolisib 1avelumab 1Vinorelbine 1Sunitinib 1Hydroxychloroquine 1Dasatinib 1DOXO-EMCH 1Cetuximab 1BN 80927 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Malignant Solid Tumour × nintedanib × Clear all
NCT01951846 2013-09-27

To Determine the Maximum Tolerated Dose (MTD) of BIBF 1120 in Patients With Solid Tumours

Boehringer Ingelheim

Phase 1 Completed
61 enrolled
Other solid neoplasm

Malignant Solid Tumour

Data powered by HemOnc (CC BY 4.0) Colophon âš¡